Valeo Financial Advisors’s Ovid Therapeutics OVID Stock Holding History

Valeo Financial Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-60	Closed	–	–	1405
2021 Q1	$0	Buy	+60	New	+$199	﹤0.01%	2138

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Valeo Financial Advisors's OVID Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Ovid Therapeutics (OVID) in Q2 2021, closing a stake of 60 shares.

Valeo Financial Advisors first reported a position in OVID in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 80 funds tracked by Wall St. Rank hold OVID as of Q2 2021.

Valeo Financial Advisors reported no remaining Ovid Therapeutics position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 60 Ovid Therapeutics shares in Q2 2021.
Valeo Financial Advisors first reported a position in Ovid Therapeutics in Q1 2021 and held it in 1 quarter.
Valeo Financial Advisors's Ovid Therapeutics position peaked at $0 in Q1 2021.
80 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.